Interferons
Citations
All
Search in:AllTitleAbstractAuthor name
Publications
(4)
Patents
Grants
Pathways
Clinical trials
Publication
Journal: Seminars in Perinatology
January/27/1982
Authors
Publication
Journal: Journal of Allergy and Clinical Immunology
June/14/1987
Abstract
There has been concern in recent years as to the health hazards of exposure to potentially carcinogenic or immunotoxic substances in the environment. This study was done to determine the effects of exposure to urea-formaldehyde foam insulation (UFFI) off products on various hematologic and immunologic parameters in subjects with asthma: complete blood count and differential, erythrocyte sedimentation rate, lymphocyte subpopulations (E-rosetting, T3, T4, T8, B73.1, and Fc receptor positive lymphocytes and large granular lymphocytes), lymphocyte response to phytohemagglutinin and formalin-treated red blood cells (Form-RBC), serum antibody against the Thomsen-Friedenreich RBC antigen and against Form-RBC, and natural killer (NK), interferon (IFN)-boosted NK (IFN-NK), and antibody-dependent cell-mediated cytotoxicity. Four control subjects with asthma from conventionally insulated homes (control group) and 23 subjects with asthma from UFFI-insulated homes (home group) were exposed to placebo, formaldehyde, dust, and UFFI off gas at levels ordinarily found in UFFI-containing homes for four separate periods in an environmental chamber. Immunologic testing was carried out before the exposure series and 1 day after completion 7 days later as part of an investigation of respiratory and possible allergic effects of such exposure. Data from the UFFI-insulated home group were not significantly different from data of the normal conventionally insulated home control group for any of the variables studied, either before or after UFFI exposure. Paired t tests comparing data from each of the two groups before and after UFFI exposure demonstrated minimal but statistically significant increases in percent eosinophils and T8 positive cells in the UFFI-insulated home group only. Although NK, relative NK, and IFN-NK were normal in all groups, IFN-NK assays by use of a low concentration of alpha-interferon demonstrated a statistically significant decrease in NK response to IFN in both the control and UFFI-insulated home groups after UFFI exposure. These differences were not observed at optimum levels of IFN stimulation. These data indicate that long-term exposure to UFFI off products in the home apparently had no effect on the immunologic parameters studied. Short-term exposure resulted in minor immunologic changes in this subject population.
Publication
Journal: European Journal of Clinical Investigation
February/12/1991
Abstract
The therapeutic principles in the management of endocrine gastroenteropancreatic (GEP) tumours include surgical extirpation of the primary tumour in the absence of metastases and medical control of symptoms in the preoperative phase. In the presence of metastases only palliative procedures are available. Tumour growth might be controlled by surgical procedures as debulking of tumour masses, medically by chemotherapy and more recently by new developments as a long-acting somatostatin analogue (SMS 201-995) and alpha-interferon. Their efficacy is currently evaluated in prospective studies. In contrast to inhibition of growth symptoms derived from excessive hormone production by GEP tumours can be well controlled. SMS 201-995 effectively prevents or at least improves flush and diarrhoea in the carcinoid syndrome, disabling diarrhoea in the Verner-Morrison syndrome and migratory erythema in the glucagonoma syndrome. SMS acts by inhibition of hormone release from the tumour and by a direct mechanism at the site of the target cell via SMS receptors present on tumour and target cells. For control of acid hypersecretion in gastrinoma patients omeprazole is superior to all former and present alternatives and replaced total gastrectomy completely. A similarly effective drug to prevent hypoglycaemia due to uncontrolled insulin release from insulinomas is not available since neither SMS nor diazoxide are effective in every insulinoma patient.
Authors
Publication
Journal: StatPearls Publishing
August/19/2019
Abstract
Many patients with chronic diseases require injections as part of their prolonged medical therapy. Hyaluronidase has been shown to enhance the systemic delivery of injectable medications and provide better treatment outcomes for these patients. Examples of current medications being using in combination with hyaluronidase include, but are not limited to: insulin in diabetes, beta interferons in multiple sclerosis, biotherapeutics in rheumatoid arthritis, immunoglobulin replacement therapy in primary immunodeficiencies, and monoclonal antibodies in cancer treatment.[1] Hyaluronidase is currently used for several other types of medical management as well.